While AKT1, AKT2, AKT3 aberrations were identified in 1.4% (138/10194), 2% (206/10194), and 1.2% (122/10194) of patients in China Pan-cancer Cohort (OrigiMed2020) (20, 22). This evidence concerns the gene AKT2 and cancer.